StocksMediumUpdated×2•Originally published 29 September 2026•Updated 30 September 2026•
1 min read
Pyxis Oncology Stock Tumbles as Offering Proceeds Slated for Phase 3 Trials
Key Facts
1Pyxis Oncology announced the commencement of a registered public offering of its common stock and pre-funded warrants.
Pyxis Oncology priced its registered public offering at $2.90 per share to fund Phase 3 clinical trials for its cancer therapeutics. The company expects to generate gross proceeds of approximately $110 million, which could potentially reach $282.6 million if all warrants are fully exercised.
The stock, PYXS, closed at $2.90 on September 28, 2026, aligning exactly with the newly announced offering price. According to a statement via GlobeNewswire, the offering consists of common stock and pre-funded warrants designed to secure the capital required for intensive late-stage clinical development.